Ibrexafungerp: A novel oral glucan synthase inhibitor

M. R. Davis; M. A. Donnelley; G. R. Thompson

doi:10.1093/mmy/myz083

Ibrexafungerp: A novel oral glucan synthase inhibitor

M. R. Davis, M. A. Donnelley, G. R. Thompson

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

Original language	English (US)
Pages (from-to)	579-592
Number of pages	14
Journal	Medical mycology
Volume	58
Issue number	5
DOIs	https://doi.org/10.1093/mmy/myz083
State	Published - Nov 23 2019
Externally published	Yes

Keywords

antifungal
aspergillosis
candidiasis
in vitro activity
in vivo studies

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.1093/mmy/myz083

Cite this

@article{67c90dda79f848a4a31156468ca6671d,

title = "Ibrexafungerp: A novel oral glucan synthase inhibitor",

abstract = "Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia. ",

keywords = "antifungal, aspergillosis, candidiasis, in vitro activity, in vivo studies",

author = "Davis, {M. R.} and Donnelley, {M. A.} and Thompson, {G. R.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s). Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.",

year = "2019",

month = nov,

day = "23",

doi = "10.1093/mmy/myz083",

language = "English (US)",

volume = "58",

pages = "579--592",

journal = "Medical Mycology",

issn = "1369-3786",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Ibrexafungerp

T2 - A novel oral glucan synthase inhibitor

AU - Davis, M. R.

AU - Donnelley, M. A.

AU - Thompson, G. R.

PY - 2019/11/23

Y1 - 2019/11/23

N2 - Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

AB - Ibrexafungerp is a novel glucan synthase inhibitor currently undergoing phase II and phase III clinical trials. This compound has demonstrated in vitro activity against clinically important fungal pathogens including Candida spp. and Aspergillus spp. It is able to retain activity against many echinocandin-resistant strains of Candida due to differential avidity for the target site compared to echinocandins. In vivo animal models have demonstrated efficacy in murine models of invasive candidiasis, aspergillosis, and pneumocystis. Due to high bioavailability, it can be administered both orally and intravenously. A favorable drug interaction and tolerability profile is observed with this compound. This review summarizes existing data that have either been published or presented at international symposia.

KW - antifungal

KW - aspergillosis

KW - candidiasis

KW - in vitro activity

KW - in vivo studies

UR - http://www.scopus.com/inward/record.url?scp=85077138326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077138326&partnerID=8YFLogxK

U2 - 10.1093/mmy/myz083

DO - 10.1093/mmy/myz083

M3 - Review article

C2 - 31342066

AN - SCOPUS:85077138326

SN - 1369-3786

VL - 58

SP - 579

EP - 592

JO - Medical Mycology

JF - Medical Mycology

IS - 5

ER -

Ibrexafungerp: A novel oral glucan synthase inhibitor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this